Best Dlbcl Podcasts (2026)

1
Episode 68. ASH 2025 Myeloma Special: MajesTEC-3 and the Bispecific Revolution with Dr. Luciano Costa 45:50

Play Pause

4d ago45:50

45:50

Join hosts Raj, Ashwin, and Eddie in this episode of Blood Cancer Talks as they welcome Dr. Luciano Costa, the first author of the NEJM manuscript on the MajesTEC-3 RCT, which was presented at ASH 2025. This episode dives deep into the trial's topline findings, capturing the nuances of the patient population, efficacy and safety data, and the futur…

1
Experts Discuss CELMoD Agents for Treating Multiple Myeloma 17:30

8d ago17:30

17:30

In this podcast episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Niels van de Donk, MD, PhD, address key questions on CELMoD agent therapy for multiple myeloma, including: Combination strategies Adverse event management Where CELMoD agents may best fit within current and future treatment strategies Presenters: Jesus Berdeja, MD Director o…

1
PulseCast: Highlights in MDS/MPNs From the 2025 ASH Annual Meeting 14:59

8d ago14:59

14:59

In this podcast episode, Rami Komrokji, MD, reviews data from select presentations in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) presented at the ASH 2025 Annual Meeting and shares expert perspectives on the clinical implications of these findings, including: Abstract 910: MANIFEST-2 96-Wk Update: Ruxolitinib + Pelabres…

1
Expert Highlights From the 2025 World Conference on Lung Cancer 24:30

13d ago24:30

24:30

In this episode, Dr John Heymach and Dr Solange Peters discuss key data presented at the IASLC World Conference on Lung Cancer including first-line maintenance in ES-SCLC (IMforte and DeLLphi-303 trials) and targeted treatment for NSCLC (FLAURA2, Beamion LUNG-1, and ARROS-1 trials). Presenters: John Heymach, MD, PhD Chair and Professor Department o…

1
PulseCast: Highlights in Multiple Myeloma From the 2025 ASH Annual Meeting 15:45

14d ago15:45

15:45

In this episode, Shaji K. Kumar, MD, reviews key highlights from ASH 2025 in multiple myeloma (MM), focusing on emerging data for bispecific antibodies and CAR T-cell therapies across earlier and later lines of treatment. The discussion covers the following: MajesTEC-3: Results from the phase III study of teclistamab + daratumumab in R/R MM Redirec…

1
PulseCast: Highlights in Lymphomas From the 2025 ASH Annual Meeting 14:25

18d ago14:25

14:25

In this podcast episode, Jeremy S. Abramson, MD, MMSc, reviews data from select presentations in lymphomas at the ASH 2025 Annual Meeting and provides perspectives on the clinical implications of these data for patients with chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL), including: CLL17: ra…

1
PulseCast: Highlights in Nonmalignant Blood Disorders From the 2025 ASH Annual Meeting 17:39

19d ago17:39

17:39

In this episode, Hanny Al-Samkari, MD, gives his thoughts on 5 key presentations from ASH 2025, and provides perspectives on the clinical implications of these data for patients with nonmalignant hematologic disorders such as ITP and vWD, including: LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase III trial of ianalumab plus e…

1
PulseCast: Highlights in Leukemias From the 2025 ASH Annual Meeting 22:20

20d ago22:20

22:20

In this podcast episode, Amir T. Fathi, MD, reviews data from select presentations in leukemias at the ASH 2025 Annual Meeting, and provides perspectives on the clinical implications of these data for patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML), including: Abstract 6: Phase II PARADIGM trial of azacitidine and venet…

1
Episode 67. Management of CMV in Hematologic Malignancies 40:01

1M ago40:01

40:01

Join hosts Eddie, Ashwin, and Raj as they welcome Dr. Michelle Yong and Dr. Gemma Reynolds, academic infectious diseases physicians from the Peter MacCallum Cancer Centre and the National Centre for Infections in Cancer, for an in-depth discussion on cytomegalovirus (CMV) management in immunocompromised hematology patients. Key Topics Covered Funda…

1
TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today? 20:37

2M ago20:37

20:37

In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including: TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan TROP2 ADCS for patients with EGFR-mutated NSCLC TIGIT-targeting agents: domv…

1
A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer 22:14

2M ago22:14

22:14

In this episode, Dr Rachel Grisham and Dr Kathleen Moore discuss newly approved treatments for low-grade serous ovarian cancer (LGSOC) and how recent research has transformed the therapeutic landscape for these patients, including: Molecular distinctions between low-grade and high-grade serous ovarian cancer that can guide therapy selection The rec…

1
CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach 26:01

2M ago26:01

26:01

In this episode, Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard, MD, PhD, discuss the emerging role of CDH6-targeting antibody–drug conjugates (ADCs) for ovarian cancer, including: Results of the phase I trial of raludotatug deruxtecan (R-DXd) in ovarian cancer Results of the phase II REJOICE-Ovarian01 study in patients with platinum-re…

1
Transforming Care in Cutaneous Squamous Cell Carcinoma: Integrating Immunotherapy Into Patient Care 35:16

2M ago35:16

35:16

In this podcast, Dr David Miller, MD, PhD, FAAD and Dr Vishal Patel, MD discuss the evolving treatment landscape and immunotherapeutic strategies for cutaneous squamous cell carcinoma (cSCC) based on key data from pivotal studies that are reshaping standards of care, including: Trials of neoadjuvant immunotherapies demonstrating remarkable response…

1
Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management 27:48

2M ago27:48

27:48

In this educational podcast discussion, Carlos M. De Castro, MD, and David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath, explore paroxysmal nocturnal hemoglobinuria (PNH). They trace the evolution of treatment from early complement inhibitors to today’s expanding therapeutic options, emphasizing how these advances have transformed patient outcomes …

1
Episode 66. International Myeloma Society 2025 Annual Meeting Updates with Dr. Alfred Garfall: The Bispecific Bonanza 52:16

3M ago52:16

52:16

This episode provides comprehensive coverage of key clinical trial updates from the 2025 International Myeloma Society (IMS) Annual Meeting in Toronto, with special focus on bispecific antibodies and novel immunotherapies across the multiple myeloma disease continuum—from smoldering disease through relapsed/refractory settings. Dr. Alfred Garfall p…

1
Advancing the Care of Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer 26:10

3M ago26:10

26:10

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative early breast cancer including insights on identifying high-risk disease considering clinical/pathological factors and gene expression assays and answering healthcare professional questions on h…

1
Advancing the Care of Patients With HR-Positive/HER2-Negative Metastatic Breast Cancer 23:57

3M ago23:57

23:57

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative metastatic breast cancer including the current treatment algorithm, implementing genomic testing for assessing molecular resistance and guiding treatment decisions, and answering healthcare pro…

1
HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancers: Testing Recommendations and New Treatment Options 37:10

3M ago37:10

37:10

In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC), including: Brief overview of BTC and GEA Approved HER2-directed therapies for BTC and GEA and their mechanisms of acti…

1
Episode 65. Circulating Tumor DNA in DLBCL with Dr. Ash Alizadeh and Dr. David Russler-Germain 53:08

3M ago53:08

53:08

In this episode of Blood Cancer Talks, hosts Eddie, Ashwin, and Raj welcome two distinguished experts to explore the cutting-edge field of circulating tumor DNA (ctDNA) in B-cell lymphomas. Dr. David Russler-Germain, a lymphoma clinician from Siteman Cancer Centre at Washington University in St. Louis, returns as a familiar voice to the podcast aud…

1
Key Decisions for Selecting Bispecific Antibodies in Follicular Lymphoma 22:53

4M ago22:53

22:53

In this episode, Dr Christopher Flowers and Dr John Allan discuss their experience with the use of CD20xCD3 bispecific antibodies in the treatment of patients with relapsed/refractory follicular lymphoma. They also their thoughts on key ongoing clinical trials with bispecific antibodies that they are excited about for their potential to change the …

1
Pancreatic Cancer Progress: Expert Insights on Treatment Choices and Collaborating with Patients 13:57

4M ago13:57

13:57

Listen in as Zev A. Wainberg, MD; Paul E. Oberstein, MD; and Mark O’Hara, MD, discuss the evolving treatment landscape for metastatic pancreatic cancer, including: How patients often present with disease-related symptoms Treatment selection considerations for the first-line and second-line setting How to approach palliative care discussions with pa…

1
Latest Advances in CAR T-Cell Therapy for Lymphomas and Multiple Myeloma 16:48

4M ago16:48

16:48

In this episode, Dr Brad Kahl and Dr Noopur Raje discuss the recent advances and emerging data for CAR T-cell therapy in lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently u…

1
CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions 20:20

4M ago20:20

20:20

In this episode, Drs William J. Gradishar, Heather McArthur, and Joanne Mortimer address audience questions from a recent live event on the use of CDK4/6 inhibitors in patients with early and metastatic breast cancer, including: Genomic testing options for assessing risk of recurrence Adjuvant treatment duration and holidays with CDK4/6 inhibitors …

1
Episode 64. Lymphoma Updates from EHA and ICML 2025 with Dr. Adrian Minson 43:03

5M ago43:03

43:03

In this episode of Blood Cancer Talks, we have Dr. Adrian Minson from the Peter MacCallum Cancer Centre to discuss the latest developments in lymphoma presented at the recent EHA and ICML meetings in June 2025. The episode focuses primarily on the emerging role of bispecific antibodies in various combinations and treatment settings for diffuse larg…

1
Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas 29:59

5M ago29:59

29:59

In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including: The clinical implications of using DLL3 as a therapeutic target The impact of emerging DLL3-targeted therapies on evolving treatment paradigms How to incorpor…

1
Highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting — Driving Knowledge to Action: Building a Better Future 1:30:31

5M ago1:30:31

1:30:31

- Treatment Updates from ASCO 2025 on Lung Cancer- Supportive Care Issues- Treatment Updates from ASCO 2025 on Colorectal Cancer- Quality-of-Life Concerns- Update on Pancreas Cancer- Supportive Care Concerns- Update on Lymphoma- Communicating with Your Health Care Team- Updates on Leukemia from ASCO- Managing Treatment Side Effects- Updates on Mela…

1
Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective 24:49

5M ago24:49

24:49

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including: Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedules Avail…

1
Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025 39:12

5M ago39:12

39:12

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings. Program Abstracts: POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCL ECHO: Rituximab-Bendamustine ±…

1
Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting 35:02

6M ago35:02

35:02

In this episode, Kevin Kalinsky, MD, MS, FASCO, and Sara M. Tolaney, MD, MPH, discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting, including: DESTINY-Breast09: phase III trial of trastuzumab deruxtecan with or without pertuzumab vs THP as first-line treatment of HER2-positive advanced/metastatic brea…

1
Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC 18:04

6M ago18:04

18:04

In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC: Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs…

1
Episode 63. Management of Follicular Lymphoma with Dr. Gilles Salles 51:37

6M ago51:37

51:37

In this episode, we discuss the management of follicular lymphoma with Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center. Here are the articles we discussed: 1. Relevance of Bone Marrow Biopsy in Follicular Lymphoma: https://pubmed.ncbi.nlm.nih.gov/35787017/ 2. TROG 99.03 (RCT of Systemic Therapy after Involved-Field Radiotherapy in Pat…

1
A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors? 22:23

6M ago22:23

22:23

In this episode, Eunice Wang, MD and Eytan Stein, MD explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care. Presenters: Eytan M. Stein, MD Chief, Leukemia Service Director, Program for Drug Development in Leukemia Associate Attending P…

1
BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025 21:24

6M ago21:24

21:24

In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including: The randomized phase III FLAIR trial The randomized phase III SEQUOIA trial The randomized phase III BRUIN CLL-321 trial Pres…

1
Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma 31:19

6M ago31:19

31:19

In this episode, Joseph W. Franses, MD, PhD; Neehar Parikh, MD, MS; and Mark Yarchoan, MD, share their thoughts on incorporating immune checkpoint inhibitors into the care of patients with HCC including: Clinical Considerations for Selecting First-line Immunotherapy Combinations for Metastatic HCC Overview of the Latest Data for the Combination of …

1
Personalized Pathways: Redefining Frontline Hodgkin Lymphoma Treatment Strategies 35:36

6M ago35:36

35:36

In this episode, Jonathan W. Friedberg, MD; Alex F. Herrera, MD; and Kara Kelly, MD, discuss the latest frontline treatment options for advanced Hodgkin lymphoma (HL) and approaches to personalizing treatment for the general patient population, older patients, and pediatric patients. This podcast was adapted from a live presentation held in May 202…

1
Experts Discuss CELMoDs in Myeloma 35:51

6M ago35:51

35:51

In this episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Sagar Lonial, MD, FACP, discuss key topics with CELMoD therapy for multiple myeloma, including: Mechanistic differences between CELMoDs and IMiDs Emerging data with CELMoDs and their potential therapeutic roles across the disease continuum of multiple myeloma The clinical implicatio…

1
Episode 62. Unpacking MIDAS Trial in Myeloma with Dr. Meera Mohan 25:05

6M ago25:05

25:05

In this episode, we dissect the phase 3 MIDAS trial in newly diagnosed transplant-eligible multiple myeloma with Dr. Meera Mohan. https://pubmed.ncbi.nlm.nih.gov/39841461/ https://pubmed.ncbi.nlm.nih.gov/40459097/By Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

1
Addressing the LGBTQI+ Health Disparities Gap 56:55

7M ago56:55

56:55

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV- The LGBTQI+ Community’s Disproportionate Cancer Burden- Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers- Barriers to Health Care Access, Including Discrimination- Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housi…

1
Addressing the LGBTQI+ Health Disparities Gap 56:55

6M ago56:55

56:55

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV- The LGBTQI+ Community’s Disproportionate Cancer Burden- Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers- Barriers to Health Care Access, Including Discrimination- Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housi…

1
Children as Caregivers for a Loved One with Cancer 56:06

7M ago56:06

56:06

- Definition of a Caregiver- What Research Tells Us About Children as Caregivers’ Well Being- Children as Caregivers- Children as Caregivers for a Sibling- Children as Caregivers for a Parent- Children as Caregivers for a Grandparent- Children as Caregivers for an Older Adult- Children as Caregivers for a Younger Adult- Children as Caregivers for C…

1
Children as Caregivers for a Loved One with Cancer 56:06

7M ago56:06

56:06

- Definition of a Caregiver- What Research Tells Us About Children as Caregivers’ Well Being- Children as Caregivers- Children as Caregivers for a Sibling- Children as Caregivers for a Parent- Children as Caregivers for a Grandparent- Children as Caregivers for an Older Adult- Children as Caregivers for a Younger Adult- Children as Caregivers for C…

1
Episode 61. Menin Inhibitors in AML with Dr. Eytan Stein 56:24

7M ago56:24

56:24

In this episode, we took a deep dive intro the landscape of menin inhibitors in AML with Dr. Eytan Stein from MSKCC. Here are the key trials and studies we discussed: ELN 2022 AML Classification https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022 Predictors of outcomes in adults with AML and K…

1
Diverse Populations Participating in Decisions About Your Care with Your Health Care Team 1:03:12

7M ago1:03:12

1:03:12

- How Being a Member of Diverse Communities May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects, & Pain Management- What to Expect from Your Relationship with Your Health Care Team: Is Your Health Care Team Providing You with Equitable, Excellent Care- What to Consider When Selecting a Cancer Care Team & Treatme…

1
Diverse Populations Participating in Decisions About Your Care with Your Health Care Team 1:03:12

7M ago1:03:12

1:03:12

- How Being a Member of Diverse Communities May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects, & Pain Management- What to Expect from Your Relationship with Your Health Care Team: Is Your Health Care Team Providing You with Equitable, Excellent Care- What to Consider When Selecting a Cancer Care Team & Treatme…

1
Current Perspectives on the Future of Cancer Research 1:05:29

7M ago1:05:29

1:05:29

- Understanding the Future of Cancer Research & Clinical Trials- Increased Focus on Earlier Detection & Treatment of Cancer- Health Care Disparities Research- Enhanced Knowledge of the Molecular Portrait of Cancer- Artificial Intelligence (AI) Driven Approaches for Diagnosis & Treatment of Cancer- Microsatellite Instability (MSI): Mutations in DNA …

1
Current Perspectives on the Future of Cancer Research 1:05:29

7M ago1:05:29

1:05:29

- Understanding the Future of Cancer Research & Clinical Trials- Increased Focus on Earlier Detection & Treatment of Cancer- Health Care Disparities Research- Enhanced Knowledge of the Molecular Portrait of Cancer- Artificial Intelligence (AI) Driven Approaches for Diagnosis & Treatment of Cancer- Microsatellite Instability (MSI): Mutations in DNA …

1
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care 51:55

7M ago51:55

51:55

- Disproportionate Burden of Cancer & Infectious Diseases on People of Color- Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care- Influence of the Local & Regional Environment in Which You Live- How Race May Impact Your Access to Oncology Care, Tre…

1
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care 51:55

7M ago51:55

51:55

- Disproportionate Burden of Cancer & Infectious Diseases on People of Color- Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care- Influence of the Local & Regional Environment in Which You Live- How Race May Impact Your Access to Oncology Care, Tre…

1
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities 35:15

7M ago35:15

35:15

In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including: Key Comorbidit…

1
Episode 60. Emergency Podcast-AQUILA and STARGLO 54:33

7M ago54:33

54:33

In this episode, we discuss the recent proceedings at the FDA ODAC meeting on AQUILA trial in smoldering myeloma and STRAGLO in R/R DLBCL, and provide an update to our audience on some of the clinically relevant data presented from those trials, along with insights from the panelists. Here is the link to the webpage with FDA briefing documents and …